tetano
Editor, Senior Moderator
Case Rep Cardiol
. 2023 Jun 22;2023:7646962.
doi: 10.1155/2023/7646962. eCollection 2023. Acute Lymphocytic Myocarditis in a Young Male Post-COVID-19
Mintje Bohné[SUP] 1 [/SUP], Sebastian Bohnen[SUP] 1 [/SUP], Stephan Willems[SUP] 1 [/SUP], Karin Klingel[SUP] 2 [/SUP], Dietmar Kivelitz[SUP] 3 [/SUP], Edda Bahlmann[SUP] 1 [/SUP]
Affiliations
Background: Lymphocytic myocarditis is a rare form of myocarditis, associated with a high mortality rate due to a high risk of sudden cardiac death. Lymphocytic myocarditis might present as a relevant extrapulmonary manifestation after coronavirus disease 2019 (COVID-19) infection. Case presentation. We report a case of a 26-year-old male with lymphocytic myocarditis, presenting with a 1-month history of increasing fatigue, palpitations, and shortness of breath. Eight weeks before, he was tested positive for SARS-CoV-2. He had received 2-dose schedule of the COVID-19 mRNA vaccine Comirnaty® (BioNTech/Pfizer) 6 months prior to his admission. Diagnostic work-up by echocardiography and cardiac magnetic resonance (CMR) imaging demonstrated a severely reduced left ventricular function and a strong midmyocardial late gadolinium enhancement (LGE). Histology and immunohistology of the endomyocardial biopsies revealed an acute lymphocytic myocarditis. Immunosuppressive therapy with a steroid taper in combination with azathioprine 300 mg/day was initiated. The patient was equipped with a LifeVest®. On day 17, a non-sustained ventricular tachycardia was documented. Follow-up CMR imaging after 3 months showed a slightly improved systolic left ventricular function, and a strong LGE was still detectable.
Conclusions: The case highlights the significance of recognizing lymphocytic myocarditis correlated to COVID-19. It is important to be vigilant also of a later presentation of cardiomyopathy in patients diagnosed with COVID-19 due to high mortality without immediate support.
. 2023 Jun 22;2023:7646962.
doi: 10.1155/2023/7646962. eCollection 2023. Acute Lymphocytic Myocarditis in a Young Male Post-COVID-19
Mintje Bohné[SUP] 1 [/SUP], Sebastian Bohnen[SUP] 1 [/SUP], Stephan Willems[SUP] 1 [/SUP], Karin Klingel[SUP] 2 [/SUP], Dietmar Kivelitz[SUP] 3 [/SUP], Edda Bahlmann[SUP] 1 [/SUP]
Affiliations
- PMID: 37397607
- PMCID: PMC10310455
- DOI: 10.1155/2023/7646962
Background: Lymphocytic myocarditis is a rare form of myocarditis, associated with a high mortality rate due to a high risk of sudden cardiac death. Lymphocytic myocarditis might present as a relevant extrapulmonary manifestation after coronavirus disease 2019 (COVID-19) infection. Case presentation. We report a case of a 26-year-old male with lymphocytic myocarditis, presenting with a 1-month history of increasing fatigue, palpitations, and shortness of breath. Eight weeks before, he was tested positive for SARS-CoV-2. He had received 2-dose schedule of the COVID-19 mRNA vaccine Comirnaty® (BioNTech/Pfizer) 6 months prior to his admission. Diagnostic work-up by echocardiography and cardiac magnetic resonance (CMR) imaging demonstrated a severely reduced left ventricular function and a strong midmyocardial late gadolinium enhancement (LGE). Histology and immunohistology of the endomyocardial biopsies revealed an acute lymphocytic myocarditis. Immunosuppressive therapy with a steroid taper in combination with azathioprine 300 mg/day was initiated. The patient was equipped with a LifeVest®. On day 17, a non-sustained ventricular tachycardia was documented. Follow-up CMR imaging after 3 months showed a slightly improved systolic left ventricular function, and a strong LGE was still detectable.
Conclusions: The case highlights the significance of recognizing lymphocytic myocarditis correlated to COVID-19. It is important to be vigilant also of a later presentation of cardiomyopathy in patients diagnosed with COVID-19 due to high mortality without immediate support.